The goal of this study is to evaluate the effect of mepolizumab on patients with COPD using MRI and CT imaging as well as breathing tests. The study will evaluate the response to this medication after 24 and 48 weeks of treatment. The main questions it aims to answer are: 1. Does mepolizumab improve ventilation defect percent as measured on 129-Xenon MRI in adults with COPD. 2. Does mepolizumab improve the amount of mucus plugs in the lungs as measured by lung CT in adults with COPD. Participants will: 1. Take mepolizumab by subcutaneous injection every 4 weeks for the duration of the study. 2. Visit Robarts 4 times over 48 weeks for tests and imaging.
Age range
55 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
To measure the effect of mepolizumab (100mg) on MRI ventilation defect percent in participants with no severe exacerbations during the study period.
Timeframe: 24-weeks and 48-weeks.
To measure the effect of mepolizumab (100 mg) on CT airway mucus-count.
Timeframe: 24-weeks and 48-weeks.